Prof. Lerchenmüller is founder and CFO of AaviGen. He is responsible for financial and business development matters as well as for data science applications within AaviGen’s development plan. Prior to AaviGen, Prof. Lerchenmüller co-founded InoCard, a cardiovascular gene therapy start-up that was sold to uniQure N.V. and entered into a development alliance with Bristol-Myers Squibb. He also worked for the health care practice of the Boston Consulting Group in New York City where his experience spans from strategy projects with executive boards of Fortune 500 companies to the execution of large transactions. Prof. Lerchenmüller holds the Assistant Professorship for Technological Innovation and Management Science at the University of Mannheim. He holds degrees in Financial Economics, Public Health with a focus on Regulatory Affairs, and Business Economics from the University of Oxford, the London School of Hygiene and Tropical Medicine, WHU, and Yale University.